Fundz

TECregen Appoints Dr. Klaas P. Zuideveld as Chief Executive Officer

PRIVATEJan 29, 2026

Position

Chief Executive Officer

Company

TECregen

Klaas P. Zuideveld
BaselBiotechnologyHealth Care

Description

TECregen, a biotechnology company, has announced the appointment of Dr. Klaas P. Zuideveld as Chief Executive Officer

Quick answer

TECregen Appoints Dr. Klaas P. Zuideveld as Chief Executive Officer (January 29, 2026). TECregen is based in Basel, Basel City, Switzerland.

Who is the new Chief Executive Officer at TECregen?
TECregen named Klaas P. Zuideveld Chief Executive Officer, announced January 29, 2026.
What did TECregen announce on January 29, 2026?
TECregen, a biotechnology company, has announced the appointment of Dr. Klaas P. Zuideveld as Chief Executive Officer
What does TECregen do?
TECregen is pioneering thymus rejuvenation to address conditions driven by impaired T-cell responses.
Where is TECregen based?
TECregen is based in Basel, Basel City, Switzerland.
Which similar companies made leadership changes around the same time?
ViCentra B.V (January 29, 2026), Elevar Therapeutics and Relay Therapeutics (January 29, 2026), Telo Genomics (January 29, 2026) and AN2 Therapeutics (January 29, 2026) also announced leadership changes within 45 days of TECregen.

Source: Fundz verified event record.

Other recent leadership changes in Biotechnology and Health Care

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at TECregen, and when

A new leader at TECregen brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day TECregen raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at TECregen, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at TECregen. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

TECregen

Location

Basel, Basel City, Switzerland

About

TECregen is pioneering thymus rejuvenation to address conditions driven by impaired T-cell responses. The company’s innovative approach focuses on revitalizing and expanding thymic epithelial cells (TECs) to replenish T cells and achieve durable improvements in immune function. By developing a pipeline of differentiated thymopoietic biologics, TECregen aims to strengthen immune recovery following transplantation or cytotoxic therapy, promote immune health, and enhance immune surveillance against cancer, ushering in a new era of immunotherapy.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment TECregen changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for TECregen's next move

Learn about Strategic plan

TECregen changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.